Background: Lunasin Targeted Extract (ET-Lun) has a pharmacology effect in inhibiting inflammation by decreasing COX-2 and iNOS expression. ET-Lun could increase apoptosis and decrease dysplasia (p > 0,05). In addition, ET-Lun could decrease EGFR expression in breast cancer rats. The acute toxicity showed ET-Lun has LD50 more than 5000 mg/kg BW and was practically non-toxic. Objective: this study aimed to determine the subchronic toxicity of ET-Lun. Methods: Male and female Sprague Dawley rats (n=40) were divided into 4 groups, the control group and treatment group ET-Lun dose of 250 mg/Kg BW, 500 mg/kg BW, and 750 mg/kg BW. The ET-Lun was administered for 90 days. On the 91st day, the animals were dissected and examined for SGOT-SGPT levels, liver histopathology, and diameter of the central vein. Results: The SGOT-SGPT levels showed no significant difference between the treatment group and the control group (p > 0.05). On microscopic observation, there was no change or damage to the liver of rats in each group. The diameter of the central vein of the rat liver shows no significant difference between the control and treatment groups. Conclusion: The ET-Lun does not produce adverse effects in liver rats after subchronic treatment.
- Subchronic toxicity